Biotechnology company Circio Holding ASA (OSE:CRNA) said on Wednesday that it has entered into a research collaboration with Universidad de Santiago de Compostela through its TraffikGene project to explore non-viral delivery of circular RNA vectors for gene and cell therapy applications.

The partnership will combine Circio's circVec platform with TraffikGene's peptide-based delivery system to evaluate targeted delivery into novel tissues.

This collaboration is designed to assess whether the peptide amphiphile carrier technology can enable efficient and prolonged delivery of circVec vectors, with enhanced tissue specificity. Activities will include high-throughput screening of delivery formulations, followed by physicochemical optimisation of selected candidates.

The research programme will progress through in vitro testing, formulation refinement, and in vivo evaluation in mouse models to measure expression kinetics, biodistribution, and delivery performance. The initiative aims to identify optimised non-viral delivery approaches to support next-generation gene and cell therapy development.